Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB-100 + Tofacitinib in Mesothelin-Expressing Solid Tumors
NCT04034238Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Antibody-Drug Conjugates (ADCs), Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of LMB-100 in pancreatic adenocarcinoma (PDAC), cholangiocarcinoma (CCA) and solid tumor (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 21 days, Percentage of Participants With Pancreatobiliary Cancer and LMB-100 Plasma Drug Levels Above Threshold 600ng/mL During Cycle 2 at Cycle 2 and 1 more. Started Aug 2019; status: completed.
02
Drugs
LMB-100
03
Conditions
pancreatic adenocarcinoma (PDAC)cholangiocarcinoma (CCA)solid tumor
Beyond the preview
Go deeper on NCT04034238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04034238.